Biotech Update Wassenaar



We have seen a very successful year for the life science industry with an historical record number of IPOs and M&A transactions in biotech and medical technologies. Also, the European biotech industry experienced a stock market boom in 2014. A total of USD 2.4bn was raised by biotech companies in Europe via the stock exchange, an increase of 25% compared to the previous year. But we also see other changes in the environment. Health systems and players are seeking more sustainable approaches, including incentives that emphasize value, driven by technologies and demographic forces.
 
Biotech Update 2015: reflection on positive developments
At this year’s Biotech Update, we want to reflect on the positive developments in the industry. With this renewed focus on delivering value to the patient, we can see even clearer that the treatment of the patient is at the center of life science companies and is a major driver for the professionals involved in these companies. Prof. Dr. Yvo Roos, professor at the department of Acute (cerebrovascular) Neurology at the Academic Medical Center (AMC) of the University of Amsterdam, will share his view on treatments for acute ischemic stroke and the results of the recent Mr. Clean study that stunned the stroke community. The main findings and insights of the EY Beyond Borders report 2015 will also be presented by Prof. Dr. Jan-Peter Balkenende. After that, we will welcome Prof. Dr. Eus van Someren, professor and head of the department of Sleep and Cognition at the Netherlands Institute of Neuroscience at the VU in Amsterdam. He will share his vision on sleep, insomnia and sleep disorders based on his research. Finally, Prof. Dr. Jaap Goudsmit is the Global Head of the Janssen Prevention Center, part of the Janssen Pharmaceutical Companies of Johnson & Johnson but also a non-fiction writer and scientist, best known for his research on AIDS and Influenza. He will speak to us, sharing his vision based on his experience as Chief Scientific Officer at Crucell and head of the Retrovirology department at the AMC of the University of Amsterdam.
 
Registration
By invitation only 
 
We hope you will join us and we are looking forward to welcoming you on June 25.
René Kuijten       Dick Hoogenberg   
Partner LSP        Partner EY Sector Life Sciences
 

 

« back to overview
Follow us

Biotech Update Wassenaar



We have seen a very successful year for the life science industry with an historical record number of IPOs and M&A transactions in biotech and medical technologies. Also, the European biotech industry experienced a stock market boom in 2014. A total of USD 2.4bn was raised by biotech companies in Europe via the stock exchange, an increase of 25% compared to the previous year. But we also see other changes in the environment. Health systems and players are seeking more sustainable approaches, including incentives that emphasize value, driven by technologies and demographic forces.
 
Biotech Update 2015: reflection on positive developments
At this year’s Biotech Update, we want to reflect on the positive developments in the industry. With this renewed focus on delivering value to the patient, we can see even clearer that the treatment of the patient is at the center of life science companies and is a major driver for the professionals involved in these companies. Prof. Dr. Yvo Roos, professor at the department of Acute (cerebrovascular) Neurology at the Academic Medical Center (AMC) of the University of Amsterdam, will share his view on treatments for acute ischemic stroke and the results of the recent Mr. Clean study that stunned the stroke community. The main findings and insights of the EY Beyond Borders report 2015 will also be presented by Prof. Dr. Jan-Peter Balkenende. After that, we will welcome Prof. Dr. Eus van Someren, professor and head of the department of Sleep and Cognition at the Netherlands Institute of Neuroscience at the VU in Amsterdam. He will share his vision on sleep, insomnia and sleep disorders based on his research. Finally, Prof. Dr. Jaap Goudsmit is the Global Head of the Janssen Prevention Center, part of the Janssen Pharmaceutical Companies of Johnson & Johnson but also a non-fiction writer and scientist, best known for his research on AIDS and Influenza. He will speak to us, sharing his vision based on his experience as Chief Scientific Officer at Crucell and head of the Retrovirology department at the AMC of the University of Amsterdam.
 
Registration
By invitation only 
 
We hope you will join us and we are looking forward to welcoming you on June 25.
René Kuijten       Dick Hoogenberg   
Partner LSP        Partner EY Sector Life Sciences
 

 

« back to overview